Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9084802 | REMPEX | Tetracycline compositions |
May, 2031
(7 years from now) | |
US9278105 | REMPEX | Tetracycline compositions |
May, 2031
(7 years from now) |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Treatment: Method of treating bacterial infections
Dosage: INJECTABLE;INJECTION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8680136 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10561675 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(7 years from now) | |
US10183034 | REMPEX | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(7 years from now) | |
US11007206 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(7 years from now) | |
US9694025 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(7 years from now) | |
US10172874 | REMPEX | Pharmaceutical compositions comprising cyclic boronic acid ester derivatives |
Aug, 2031
(7 years from now) | |
US11376237 | REMPEX | Methods of treating bacterial infections |
Apr, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 29, 2022 |
Generating Antibiotic Incentives Now (GAIN) | Aug 29, 2027 |
Drugs and Companies using MEROPENEM; VABORBACTAM ingredient
NCE-1 date: 2026-08-29
Market Authorisation Date: 29 August, 2017
Treatment: Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae sp...
Dosage: POWDER;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic